Familial Mediterranean fever (FMF) is the most frequent autoinflammatory disease which can be well controlled with lifelong use of colchicine. Daily colchicine use has been shown to reduce the frequency, severity, and duration of attacks. Colchicine also has been found to be effective in decreasing the prevalence of amyloidosis. Therapeutic oral dose of colchicine (0.5-2.0 mg/ day) may cause cramping, abdominal pain, hyperperistalsis, diarrhea and vomiting. Besides, colchicine may rarely cause bone marrow failure, agranulocytosis and/ or thrombocytopenia as well. Here in we report two pediatric cases of FMF who developed trombocytopenia after colchicine medication and call attention to colchicine related trombocytopenia.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
